TB-500, CJC-1295, Ipamorelin: Legal Status in 2026

Peptide Regulation & FDA

3 peptides in limbo

TB-500, CJC-1295, and ipamorelin were banned from compounding in 2023, partially unbanned in 2024, and promised reclassification in 2026. None of that has resolved their legal status.

FDA Category 2 Interim Policy, 2023-2026

FDA Category 2 Interim Policy, 2023-2026

View as image

Three of the most widely used peptides in compounding medicine hit a wall in late 2023. The FDA placed TB-500 (a fragment of thymosin beta-4), CJC-1295 (a long-acting growth hormone-releasing hormone analog), and ipamorelin (a selective growth hormone secretagogue) on its Category 2 list, effectively banning compounding pharmacies from preparing them. As part of a broader FDA crackdown on compounded peptides, these three substances went from routine prescriptions to regulatory gray zones overnight.

Since then, the story has gotten more complicated, not less. Nominations were withdrawn. Advisory committees met. A cabinet secretary made promises on a podcast. And as of March 2026, the legal status of TB-500, CJC-1295, and ipamorelin remains unresolved. Here is exactly where each one stands, what the research behind them actually shows, and what the announced reclassification does and does not change.

What Category 2 Means and Why It Matters

The FDA maintains an interim policy for bulk drug substances used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. Category 1 substances can be compounded by licensed pharmacies with a valid prescription. Category 2 substances cannot. The distinction is binary: a substance is either available for compounding or it is not.

In late 2023, the FDA moved approximately 19 peptides from Category 1 to Category 2, citing "risk for immunogenicity, peptide-related impurities, and limited safety-related information." TB-500, CJC-1295, and ipamorelin were all included. This applied to both 503A traditional compounding pharmacies and 503B outsourcing facilities.

The Category 2 designation was not a finding that these peptides are dangerous. It was a determination that the FDA had unresolved questions about their safety profile when produced outside the controls of an FDA-approved manufacturing process. The distinction matters: none of these peptides have been FDA-approved, but the compounding ban was about manufacturing standards, not clinical evidence.

For a full breakdown of how the Category 2 system works and why BPC-157 was the most prominent target, see BPC-157 and the FDA: The Category 2 Classification Explained.

TB-500: The Fragment That Never Had a Nominator

TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid peptide involved in cell migration, angiogenesis, and wound repair. In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and 61% at 7 days compared to saline controls.^[3] A follow-up study demonstrated that thymosin beta-4 accelerated wound healing in both diabetic (db/db) and aged mice, with a seven-amino-acid synthetic fragment (LKKTETQ) producing comparable effects to the full-length molecule.^[4]

The research base for thymosin beta-4 in tissue repair is genuinely substantial. Dozens of animal studies spanning cardiac, dermal, corneal, and neurological models have documented its regenerative properties. For a deeper look at the evidence on muscle repair specifically, see TB-500 for Muscle Repair: The Evidence on Regeneration. The comparison between TB-500 and BPC-157, two peptides often discussed together, is covered in TB-500 vs BPC-157: How Two Healing Peptides Compare.

The regulatory problem for TB-500 is more fundamental than for CJC-1295 or ipamorelin. When the FDA placed peptides on Category 2 and invited nominators to submit safety data for PCAC review, TB-500 had no nominator step forward. CJC-1295 and ipamorelin had their nominations withdrawn in September 2024 (which paradoxically removed them from Category 2). TB-500 was never formally nominated for the 503A bulks list in the first place.

This means TB-500 has no pathway back through the PCAC review process unless someone submits a new nomination with supporting safety data. As of March 2026, no such nomination has been filed. The RFK Jr. reclassification announcement referenced "approximately 14 peptides," and while specific names were not confirmed in every reporting source, thymosin beta-4/TB-500 was frequently listed among them. Whether this announcement translates into formal action remains to be seen.

The underlying mechanism of thymosin beta-4 is well-characterized: it promotes cell migration through its actin-binding domain and stimulates angiogenesis in wound beds.^[3] What it lacks is any human clinical trial data. Every wound healing study has been conducted in rodents. This absence of human data was central to the FDA's concerns about compounding safety. For more on the cell migration mechanism, see How Thymosin Beta-4 Promotes Cell Migration and Wound Healing.

CJC-1295: One Human Trial, Extended Half-Life, Cardiac Questions

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that covalently binds to endogenous albumin after injection, extending its half-life from minutes to days. In the only published human trial, subcutaneous CJC-1295 produced dose-dependent increases in mean plasma GH concentrations of 2- to 10-fold lasting 6 or more days, and IGF-I elevations of 1.5- to 3-fold lasting 9 to 11 days.^[1] The estimated half-life was 5.8 to 8.1 days. After multiple doses, IGF-I levels remained above baseline for up to 28 days. No serious adverse reactions were reported in that trial.

An animal study in GHRH knockout mice confirmed that daily CJC-1295 administration normalized body weight, body length, and body composition, with evidence of somatotroph cell proliferation in the pituitary.^[5]

The FDA's safety concerns focused on cardiovascular effects. The agency warned of "increased heart rate and systemic vasodilatory reaction," including flushing, warmth, and transient hypotension. These are pharmacologically predictable effects of GHRH analogs and were noted in the Teichman trial as mild adverse events.

When the FDA searched its own adverse event database (FAERS) for CJC-1295 reports through June 2024, it retrieved two reports, both of which were excluded due to insufficient information or absence of actual adverse events. A literature search through the same date found no domestic case reports describing adverse events. This is a notable gap: the FDA cited safety concerns for a substance with essentially no reported adverse events in its own surveillance system.

CJC-1295's nominations were withdrawn in September 2024, removing it from Category 2. The PCAC reviewed CJC-1295 (including free base, acetate, DAC, and DAC acetate forms) on December 4, 2024. The committee did not recommend including CJC-1295 on the 503A bulks list. This means CJC-1295 currently exists in regulatory limbo: not on Category 2, not on the approved bulks list, and not FDA-approved.

CJC-1295 is frequently combined with ipamorelin in clinical practice, and the two peptides have complementary mechanisms. CJC-1295 extends the duration of GH release while ipamorelin provides selective GH stimulation without cortisol elevation. For the detailed pharmacology, see CJC-1295: The Growth Hormone Releasing Hormone Analog Explained and How CJC-1295 Stimulates Growth Hormone: Mechanism of Action. The distinction between CJC-1295 with and without DAC (Drug Affinity Complex) is covered in CJC-1295 with DAC vs without DAC: What's the Difference?.

Ipamorelin: The Most Selective GH Secretagogue With No FDA Path

Ipamorelin holds a unique position among growth hormone secretagogues. In the landmark 1998 pharmacological characterization, Raun and colleagues demonstrated that ipamorelin released GH with potency comparable to GHRP-6 but did not increase ACTH, cortisol, or prolactin at any dose tested, including doses more than 200-fold higher than the ED50 for GH release.^[2] No other GH secretagogue has replicated this selectivity profile. GHRP-6 and GHRP-2, by comparison, both raised cortisol and ACTH levels.

In a 15-day rat study, ipamorelin produced dose-dependent increases in longitudinal bone growth rate, from 42 micrometers/day in controls to 52 micrometers/day at the highest dose, without desensitization of the GH response over the treatment period.^[6] Pharmacokinetic evaluation showed ipamorelin had approximately 20% nasal bioavailability in rats, with systemic clearance 5-fold lower than GHRP-6.^[7]

Like CJC-1295, ipamorelin acetate was removed from Category 2 in September 2024 after its nominator withdrew. The PCAC reviewed ipamorelin at its October 29, 2024 meeting alongside ibutamoren and kisspeptin-10. The committee did not recommend inclusion on the 503A bulks list.

The FDA's stated concerns for ipamorelin centered on immunogenicity risk and peptide-related impurities. The immunogenicity concern applies generically to all injectable peptides produced outside GMP-certified manufacturing, not to ipamorelin specifically. The published safety data, while limited to short-term studies, shows a remarkably clean side effect profile. In the Raun study, ipamorelin at the effective GH-releasing dose produced no changes in FSH, LH, PRL, or TSH.^[2]

For more on ipamorelin's selectivity advantage, see Ipamorelin: The Selective Growth Hormone Secretagogue and Ipamorelin vs Other GHRPs: Cortisol, Prolactin, and Selectivity.

The PCAC Reviews: What Happened and What It Means

The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that evaluates whether bulk drug substances should be included on the list of substances eligible for compounding. Two meetings in late 2024 addressed the peptides in question.

October 29, 2024: The PCAC reviewed ipamorelin, ibutamoren (MK-677), and kisspeptin-10. The committee evaluated the submitted safety and clinical data. For ipamorelin, the available evidence consisted primarily of the Raun 1998 pharmacological characterization, short-term animal studies, and the absence of controlled human clinical trials.

December 4, 2024: The PCAC reviewed AOD-9604, CJC-1295 (in multiple salt forms including DAC variants), and thymosin alpha-1. For CJC-1295, the Teichman 2006 human trial was the primary clinical evidence.

In both meetings, the PCAC did not recommend adding these substances to the 503A bulks list. This was not a determination that the peptides are harmful. It reflected the committee's assessment that the submitted data packages did not meet the evidentiary threshold for inclusion.

The PCAC process has a structural limitation: it requires someone to nominate a substance and submit supporting data. For peptides that are not FDA-approved and have no pharmaceutical company sponsor, the nomination typically comes from compounding pharmacies or physician groups. These nominators may lack the resources to compile the comprehensive safety dossiers that the committee expects.

The RFK Jr. Announcement: Promise vs. Policy

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced plans to move approximately 14 of the 19 peptides on the Category 2 list back to Category 1. The announcement was made on The Joe Rogan Experience podcast, not through a formal FDA communication.

The specific peptides expected to return include TB-500, CJC-1295, ipamorelin, BPC-157, thymosin alpha-1, AOD-9604, GHK-Cu, and several others. The full breakdown of which peptides were named and what the announcement entails is covered separately, and the political context behind the decision is worth understanding.

As of March 25, 2026, no formal FDA reclassification has been published. The Federal Register has not posted a notice of reclassification for any of the 14 peptides. Until the FDA formally updates the Category 2 list, the legal status of these peptides for compounding remains technically unchanged.

This gap between announcement and action is significant. Compounding pharmacies that begin preparing these peptides based on the announcement alone would be doing so without legal authorization. The announcement creates political pressure for the FDA to act but does not itself constitute regulatory change.

In November 2025, members of Congress sent a letter to Secretary Kennedy urging action on peptide reclassification. Legal challenges, including the Evexias/Farmakeio lawsuit arguing that the FDA bypassed proper rulemaking procedures when it created the Category 2 list, had already pressured the agency. The legal challenge that forced FDA's hand is a separate and important piece of this story.

What Reclassification Would and Would Not Change

If the FDA formally moves TB-500, CJC-1295, and ipamorelin back to Category 1, licensed compounding pharmacies could legally prepare them with a valid prescription. This would restore the status quo that existed before late 2023.

Reclassification would not make these peptides FDA-approved. It would not create standardized dosing protocols. It would not require compounding pharmacies to follow the same manufacturing standards as FDA-approved drug manufacturers. It would not generate new clinical trial data. And it would not change the fundamental evidence gap: none of these three peptides have completed the clinical trial process required for FDA approval.

The distinction between compounding access and FDA approval is critical. What Reclassification Does NOT Mean: It's Not the Same as FDA Approval covers this distinction in detail. Compounded peptides are legal prescriptions prepared by licensed pharmacies, but they carry different quality assurance standards than FDA-approved drugs. The FDA's original concern about impurities and immunogenicity in compounded peptides remains valid regardless of category status.

For comparison, sermorelin, a GHRH analog that was FDA-approved (though later discontinued by its manufacturer), went through the full regulatory process. The difference in evidence requirements between FDA approval and compounding eligibility is vast. See Sermorelin: The Original Growth Hormone Releasing Peptide for context on what a fully approved GH peptide pathway looks like.

The Bottom Line

TB-500, CJC-1295, and ipamorelin exist in a regulatory no-man's-land as of March 2026. The Category 2 ban disrupted compounding access in 2023. PCAC reviews in 2024 did not restore it. The RFK Jr. announcement in February 2026 promised reclassification, but no formal FDA action has followed. The underlying science for each peptide ranges from strong preclinical evidence (TB-500's wound healing data, ipamorelin's selectivity profile) to limited but positive human data (CJC-1295's single RCT), but none of them have pursued FDA approval. Until the FDA publishes a formal reclassification, these peptides remain in limbo between political promise and regulatory reality.

Frequently Asked Questions

Are TB-500, CJC-1295, and ipamorelin legal in 2026?

As of March 2026, these peptides cannot legally be compounded under Section 503A. They were removed from Category 2 in September 2024 after nominators withdrew, but the PCAC did not recommend them for the 503A bulks list. HHS Secretary RFK Jr. announced plans to reclassify them to Category 1 in February 2026, but no formal FDA action has been published. Until the FDA updates its category list, compounding remains unauthorized.

What is the difference between Category 1 and Category 2 peptides?

Category 1 bulk drug substances can be used by licensed compounding pharmacies to prepare medications with a valid prescription. Category 2 substances cannot be compounded due to unresolved safety questions identified by the FDA. The categories are part of the FDA's interim policy under Section 503A of the FD&C Act. Moving from Category 2 to Category 1 restores compounding access but is not the same as FDA approval.

Why did the FDA ban peptide compounding in 2023?

The FDA cited three primary concerns: risk of immunogenicity (the body mounting an immune response against the peptide), peptide-related impurities from compounding processes, and limited safety information for many of the affected substances. The agency moved approximately 19 peptides to Category 2, preventing compounding pharmacies from preparing them regardless of prescription validity.

Is ipamorelin safer than other growth hormone peptides?

Ipamorelin has the most selective GH-releasing profile of any tested secretagogue. In the Raun 1998 study, it did not increase cortisol, ACTH, or prolactin even at 200 times the effective GH dose, while GHRP-6 and GHRP-2 both elevated these hormones.^[2] This selectivity suggests a cleaner side effect profile, but long-term human safety data does not exist because ipamorelin never entered the FDA approval process.

Has CJC-1295 been tested in humans?

One randomized, placebo-controlled, double-blind trial tested CJC-1295 in healthy adults. Single injections produced GH increases of 2- to 10-fold lasting 6+ days and IGF-I elevations of 1.5- to 3-fold lasting 9 to 11 days.^[1] No serious adverse events were reported. This is the only published human trial. The FDA's FAERS database search through June 2024 found no qualifying adverse event reports.

When will peptide reclassification actually happen?

No timeline has been confirmed. HHS Secretary Kennedy announced the plan on February 27, 2026, but the FDA must publish a formal notice in the Federal Register updating the Category 2 list. This process typically involves a notice-and-comment period. As of late March 2026, no such notice has been published. Political pressure from Congress and ongoing legal challenges may accelerate the timeline, but no date is guaranteed.